Company Overview: CELG

Upcoming Projects (CELG)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (CELG)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (CELG)

Analyzing the recent Phase 2 Etrasimod data and comparing it to Celgene's ozanimod in ulcerative colitis patients
Tickers: ARNA, CELG
Execute By: Mar 23, 2018
What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma?
Ticker: CELG
Execute By: Aug 31, 2016

Upcoming & Overdue Catalysts (CELG)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CELG)

Celgene's (CELG) INREBIC (Fedratinib) gains FDA Approval as once-daily oral treatment in Myelofibrosis (bone marrow cancer)
Tickers: CELG, BMY
Occurred on: Aug 16, 2019
Celgene's(CELG) OTEZLA in Behcet’s Disease PDUFA date expected July 21, 2019
Ticker: CELG
Occurred on: Jul 19, 2019
Phase 3 STYLE Study of Celgene's (CELG) OTEZLA (apremilast) in Moderate to Severe Scalp Psoriasis Results Presented
Ticker: CELG
Occurred on: Oct 08, 2018
Celgene (CELG) Phase III data readout of AUGMENT trial testing Revlimid in treating relapsed and/or refractory Follicular lymphoma expected by end of 2017
Ticker: CELG
Occurred on: Jul 23, 2018
Celgene (CELG) expects topline data readout in mid-2018 for Phase 3 luspatercept study in patients at low risk Myelodysplastic syndromes (MDS)
Ticker: CELG
Occurred on: Jul 09, 2018
Agios Pharma (AGIO) to complete Phase 1 Study of AG-881 in patients with Hematologic Malignancies With an IDH1 or IDH2 Mutation in Q1 2018
Tickers: AGIO, CELG
Occurred on: Jun 01, 2018
Celgene (CELG) 2018 data readout for Phase 3 OPTIMISM trial, testing POMALYST and IMNOVID in patients with relapsed refractory myeloma
Ticker: CELG
Occurred on: Feb 06, 2018
Celgene Expected to Complete Four Phase 3 Trials of ABRAXANE in Different Indications in 2017
Tickers: CELG, RHHBY
Occurred on: Jan 19, 2018
Celgene (CELG) Phase III data readout of RELEVANCE trial testing Revlimid in previously untreated follicular lymphoma expected by end of 2017
Ticker: CELG
Occurred on: Dec 21, 2017
Celgene discontinues GED-0301 (mongersen) Inflammatory Bowel Disease Program's phase III REVOLVE trial (CD-002) and the extension trial (SUSTAIN, CD-004)
Ticker: CELG
Occurred on: Oct 19, 2017
Celgene (CELG) and Agios pharmaceuticals (AGIO) collaborative product IDHIFA (enasidenib), treatment for acute myeloid leukemia (AML) with IDH2 mutation, granted FDA priority review, with PDUFA decision due August 30
Tickers: CELG, AGIO
Occurred on: Aug 01, 2017
Agios Pharma (AGIO) to complete Phase 1/2 Study of AG-221 in Subjects with Hematologic Malignancies with an IDH2 Mutation in September 2017
Tickers: AGIO, CELG
Occurred on: Jun 24, 2017
Agios Pharma (AGIO) to Complete Phase 1 study of AG-120 in Subjects With Advanced Solid Tumors with an IDH1 Mutation in August 2017
Tickers: AGIO, CELG
Occurred on: Jun 03, 2017
Agios Pharma (AGIO) to complete Phase 1 study of AG-120 in subjects With Advanced Hematologic Malignancies With an IDH1 Mutation in September 2017
Tickers: AGIO, CELG
Occurred on: Jun 03, 2017
Celgene (CELG) Expects Phase 3 RADIANCE Confirmatory Trial Data in Q2 Evaluating Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
Ticker: CELG
Occurred on: May 22, 2017
European Commission Approves Celgene's (CELG) REVLIMID for the Maintenance Treatment of Adult Patients with Newly Diagnosed Multiple Myeloma Who Have Undergone an Autologous Stem Cell Transplant
Ticker: CELG
Occurred on: Feb 24, 2017
FDA Approves Celgene's (CELG) REVLIMID in Treating Multiple Myeloma (MM) Following Autologous Stem Cell Transplant (ASCT)
Ticker: CELG
Occurred on: Feb 22, 2017
England's National Institute for Health and Care Excellence (NICE) Recommends Celgene's (CELG) Otezla for Approval to Treat Adult Patients with Active Psoriatic Arthritis
Ticker: CELG
Occurred on: Dec 22, 2016
Data on Early Onset of Efficacy for Oral OTEZLA (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology
Ticker: CELG
Occurred on: Nov 14, 2016
Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis Presented
Ticker: CELG
Occurred on: Oct 17, 2016
Celgene (CELG) Announces Phase 1b Top-Line Data From CD-001 Evaluating GED-0301 in Patients with Active Crohn's Disease
Tickers: CELG, GLPG
Occurred on: Oct 16, 2016
Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year
Ticker: CELG
Occurred on: Jul 25, 2016
Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016
Ticker: CELG
Occurred on: Jul 25, 2016
Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
Ticker: CELG
Occurred on: Jul 25, 2016
REVLIMID (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Ticker: CELG
Occurred on: Jul 15, 2016
Celgene Announces Additional $3 Billion Share Repurchase Authorization
Ticker: CELG
Occurred on: Jun 15, 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
Tickers: CELG, XLRN
Occurred on: Jun 10, 2016
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
Ticker: CELG
Occurred on: Jun 04, 2016
Agios (AGIO) Announces Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
Tickers: AGIO, CELG
Occurred on: Mar 30, 2016
Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
Ticker: CELG
Occurred on: Mar 18, 2016
Celgene Presents Long Term Safety Data on Oral Otezla
Ticker: CELG
Occurred on: Mar 07, 2016
Allergen Submits Filing to FDA for the Generic Manufacturing and Marketing of Celgene's Abraxane - Celgene to Defend it's Patent Rights
Tickers: CELG, AGN
Occurred on: Mar 07, 2016
Celgene Releases Interim Analyses on Endpoints in Phase 3 ABOUND Study of ABRAXANE on Patients with Non-Small Cell Lung Cancer
Ticker: CELG
Occurred on: Feb 27, 2016
Celgene Announces Phase 2 Data from RADIANCE Trial of Ozanimod
Ticker: CELG
Occurred on: Feb 18, 2016
Celgene Settles REVLIMID Patent Litigation with Natco Pharma Ltd. of India, Natco's U.S. partner, Arrow International Limited, and Arrow's parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc)
Ticker: CELG
Occurred on: Dec 22, 2015
Agios Pharma (AGIO) data from Phase 1 trial of AG-120 underwhelms investors
Tickers: AGIO, CELG
Occurred on: Nov 09, 2015
CymaBay (CBAY) to Present Two Phase 2 Studies of Arhalofenate for Gout Patients at the American College of Rheumatology Annual Meeting
Tickers: CBAY, CELG, AZN, REGN
Occurred on: Nov 07, 2015
Celgene's (CELG) VIDAZA Cleared By European Commission for New Indication to Include Adult Patients 65 Years and Older with Acute Myeloid Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation
Ticker: CELG
Occurred on: Oct 30, 2015
Theravance Biopharma (TBPH) announces new developmental partnership with Celgene (CELG) for TD-6450, its multivalent NS5A inhibitor
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Theravance Biopharma (TBPH) and Celgene (CELG) initiate Phase 2a clinical trial of TD-6450 to treat patients with Hepatitis C virus
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Theravance Biopharma (TBPH) announces new development partner, Celgene (CELG), for its multivalent NS5A inhibitor TD-6450
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Celgene (CELG) Presents Phase 2 Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis at AGG Plenary Session
Ticker: CELG
Occurred on: Oct 19, 2015
Janssen's (JNJ) STELARA Successful in Phase 3 Chrone's Study
Tickers: JNJ, CELG
Occurred on: Oct 19, 2015

Strategic Initiatives (CELG)

Celgene announces collaboration with Vividion Therapeutics to develop small molecule therapies
Tickers: CELG, Vividion Therapeutics
Announcement Date: Mar 05, 2018
Celgene (CELG) and Agios (AGIO) Ink Collaboration Agreement with Abbott (ABT) to Develop and Commercialize Companion Diagnostic Tests for Certain Leukemia Patients
Tickers: CELG, ABT, AGIO
Announcement Date: Oct 12, 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
Tickers: CELG, AGIO
Announcement Date: May 17, 2016

CELG Overview